PL2391638T3 - Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania - Google Patents

Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania

Info

Publication number
PL2391638T3
PL2391638T3 PL10702615T PL10702615T PL2391638T3 PL 2391638 T3 PL2391638 T3 PL 2391638T3 PL 10702615 T PL10702615 T PL 10702615T PL 10702615 T PL10702615 T PL 10702615T PL 2391638 T3 PL2391638 T3 PL 2391638T3
Authority
PL
Poland
Prior art keywords
sequences
vectors containing
amino acid
nucleic acid
containing same
Prior art date
Application number
PL10702615T
Other languages
English (en)
Inventor
Stefano Colloca
Alfredo Nicosia
Riccardo Cortese
Virginia Ammendola
Maria Ambrosio
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2009/000672 external-priority patent/WO2010085984A1/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of PL2391638T3 publication Critical patent/PL2391638T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL10702615T 2009-02-02 2010-02-02 Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania PL2391638T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/EP2009/000672 WO2010085984A1 (en) 2009-02-02 2009-02-02 Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
US17262409P 2009-04-24 2009-04-24
US17485209P 2009-05-01 2009-05-01
US26634209P 2009-12-03 2009-12-03
EP10702615.5A EP2391638B1 (en) 2009-02-02 2010-02-02 Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
PCT/EP2010/000616 WO2010086189A2 (en) 2009-02-02 2010-02-02 Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof

Publications (1)

Publication Number Publication Date
PL2391638T3 true PL2391638T3 (pl) 2018-11-30

Family

ID=45561183

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10702615T PL2391638T3 (pl) 2009-02-02 2010-02-02 Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania

Country Status (17)

Country Link
US (3) US9718863B2 (pl)
EP (2) EP2391638B1 (pl)
JP (2) JP5882741B2 (pl)
KR (2) KR101763093B1 (pl)
CN (1) CN102300872A (pl)
AU (3) AU2010209938A1 (pl)
BR (1) BRPI1008018A2 (pl)
CA (2) CA3108979A1 (pl)
ES (1) ES2898235T3 (pl)
IL (2) IL214097B (pl)
MX (1) MX2011007980A (pl)
NZ (1) NZ594355A (pl)
PL (1) PL2391638T3 (pl)
RU (1) RU2604815C2 (pl)
SG (2) SG172935A1 (pl)
SI (1) SI2391638T1 (pl)
WO (1) WO2010086189A2 (pl)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE039908T2 (hu) * 2009-02-02 2019-02-28 Glaxosmithkline Biologicals Sa Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk
AU2010314842A1 (en) 2009-11-09 2012-05-31 Genvec, Inc. Methods of propagating monkey adenoviral vectors
TR201902214T4 (tr) 2010-04-16 2019-03-21 Glaxosmithkline Biologicals Sa Şempanze adenoviral vektörü-bazlı filovirüs aşıları.
EP2643465B1 (en) * 2010-11-23 2016-05-11 The Trustees Of The University Of Pennsylvania Subfamily e simian adenovirus a1321 and uses thereof
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
TW201318637A (zh) 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
TW201321016A (zh) 2011-09-29 2013-06-01 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（二）
IN2014DN03061A (pl) 2011-10-05 2015-05-15 Genvec Inc
US9617560B2 (en) 2011-10-05 2017-04-11 Genvec, Inc. Simian (gorilla) adenovirus or adenoviral vectors and methods of use
US9233153B2 (en) 2011-10-05 2016-01-12 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
DK2825640T3 (en) 2012-03-12 2016-08-01 Crucell Holland Bv BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END
SG11201406592QA (en) 2012-05-04 2014-11-27 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
KR20150014505A (ko) * 2012-05-18 2015-02-06 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 아과 e 원숭이 아데노바이러스 a1302, a1320, a1331 및 a1337 및 이것들의 사용
HK1210475A1 (en) 2012-05-29 2016-04-22 Genvec, Inc. Herpes simplex virus vaccine
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
PL2869841T3 (pl) 2012-07-05 2022-01-24 Glaxosmithkline Biologicals Sa Nowe schematy prime-boost wykorzystujące polipeptydy immunogenne kodowane przez polinukleotydy
EP4631509A2 (en) 2012-11-16 2025-10-15 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and use thereof
JP6576326B2 (ja) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍溶解性アデノウイルス組成物
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
ME03442B (me) 2013-04-25 2020-01-20 Janssen Vaccines & Prevention Bv Stabilizovani rastvorljivi pre-fuzioni rsv f polipeptidi
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
CA2951430A1 (en) 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
AU2015311868B2 (en) 2014-09-03 2018-11-22 Bavarian Nordic A/S Methods and compositions for enhancing immune responses
PT3656395T (pt) 2014-09-03 2024-02-09 Bavarian Nordic As Métodos e composições para induzir imunidade protetora contra infeção por filovírus
WO2017025782A1 (en) 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines
AP2017009846A0 (en) 2014-09-26 2017-03-31 Beth Israel Deaconess Medical Ct Inc Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
CN107949397A (zh) 2015-02-13 2018-04-20 特兰斯吉恩股份有限公司 免疫治疗疫苗和抗体组合治疗
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
US10570417B2 (en) 2015-04-14 2020-02-25 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
AU2016264027A1 (en) 2015-05-15 2017-08-31 Curevac Ag Prime-boost regimens involving administration of at least one mRNA construct
GB201514772D0 (en) * 2015-08-19 2015-09-30 Glaxosmithkline Biolog Sa Adenovirus polynucleotides and polypeptides
WO2016198599A1 (en) * 2015-06-12 2016-12-15 Glaxosmithkline Biologicals S.A. Adenovirus polynucleotides and polypeptides
BE1024824B1 (fr) * 2015-06-12 2018-07-13 Glaxosmithkline Biologicals Sa Polynucleotides et polypeptides d'adenovirus
EP3319634B1 (en) 2015-07-07 2019-08-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
EP3319633B1 (en) 2015-07-07 2020-11-11 Janssen Vaccines & Prevention B.V. Vaccine against rsv
GB201513176D0 (en) 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
SMT202100623T1 (it) 2015-12-15 2022-01-10 Janssen Vaccines & Prevention Bv Antigeni del virus dell'immunodeficienza umana, vettori, composizioni, e metodi di utilizzo degli stessi
TWI654302B (zh) 2016-01-19 2019-03-21 輝瑞股份有限公司 癌症疫苗
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
KR20220163505A (ko) 2016-02-23 2022-12-09 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
DK3436591T5 (da) 2016-03-31 2024-09-16 The European Molecular Biology Laboratory Adenovirale coat-protein-afledte transportvehikler
IL262109B2 (en) 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V vaccine against rsv
EP3439672B1 (en) 2016-04-05 2020-11-25 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f protein for use in the prophylaxis of rsv infection
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
ES2829272T3 (es) 2016-05-12 2021-05-31 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
AU2017283118B2 (en) 2016-06-20 2019-02-07 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
GB2549809C (en) * 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector
US10925956B2 (en) 2016-07-15 2021-02-23 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
US10925955B2 (en) 2016-07-15 2021-02-23 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a Marburg virus infection
MX2019002178A (es) 2016-08-23 2019-09-18 Glaxosmithkline Biologicals Sa Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
CN110036020A (zh) 2016-12-09 2019-07-19 葛兰素史密丝克莱恩生物有限公司 具有狂犬病病毒抗原的黑猩猩腺病毒构建体
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
JP2019536468A (ja) 2016-12-12 2019-12-19 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍を標的にする合成アデノウイルスおよびその使用
GB201701239D0 (en) * 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
WO2018146205A1 (en) 2017-02-09 2018-08-16 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
WO2018185732A1 (en) 2017-04-06 2018-10-11 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
JP2020518648A (ja) 2017-05-08 2020-06-25 グリットストーン オンコロジー インコーポレイテッド アルファウイルス新生抗原ベクター
AU2018265395B2 (en) * 2017-05-10 2025-04-10 Cameron Day Compositions and methods of use of Arc capsids
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
KR20200015759A (ko) 2017-06-15 2020-02-12 얀센 백신스 앤드 프리벤션 비.브이. Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법
RU2762854C2 (ru) * 2017-07-05 2021-12-23 Ноуском Аг Последовательности нуклеиновых кислот и аминокислотные последовательности аденовирусов человекообразных обезьян, исключая человека, содержащие их векторы, и их применения
AU2018300295A1 (en) 2017-07-11 2020-01-23 Pfizer Inc. Immunogenic compositions comprising CEA MUC1 and TERT
EP3651798A1 (en) 2017-07-12 2020-05-20 Nouscom AG Neoantigen vaccine composition for treatment of cancer
US11649467B2 (en) 2017-07-21 2023-05-16 Glaxosmithkline Biologicals Sa Chikungunya virus antigen constructs
SG11202000019RA (en) 2017-07-28 2020-02-27 Janssen Vaccines & Prevention Bv Methods and compositions for heterologous reprna immunizations
WO2019053109A1 (en) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
JP2020537526A (ja) 2017-10-16 2020-12-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｒｓｖ抗原性タンパク質又はその断片をコードする２つの発現カセットを有するアデノウイルスベクター
WO2019076892A1 (en) 2017-10-16 2019-04-25 Glaxosmithkline Biologicals Sa ENHANCED PROMOTER
BR112020007413A2 (pt) 2017-10-16 2020-12-08 Glaxosmithkline Biologicals S.A. Vetores adenovirais com dois cassetes de expressão
WO2019076877A1 (en) 2017-10-16 2019-04-25 Glaxosmithkline Biologicals Sa ADENOVIRAL VECTORS FOR REPLICATION
MX2020004488A (es) 2017-10-31 2020-08-13 Janssen Vaccines & Prevention Bv Adenovirus y usos de estos.
KR20200083510A (ko) 2017-10-31 2020-07-08 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 및 이의 용도
WO2019086461A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
KR20200077559A (ko) * 2017-10-31 2020-06-30 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 및 이의 용도
CA3078692A1 (en) 2017-11-03 2019-05-09 Nouscom Ag Vaccine t cell enhancer
BR112020007884A2 (pt) 2017-11-20 2020-11-03 Janssen Pharmaceuticals, Inc. método de proporcionar uma administração segura de vetores adenovirais que codificam um antígeno de vírus zika
EP3723771A4 (en) 2017-12-11 2022-04-06 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and uses thereof
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
SG11202005710YA (en) 2017-12-19 2020-07-29 Janssen Sciences Ireland Unlimited Co Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
CA3085975A1 (en) 2017-12-20 2019-06-27 Glaxosmithkline Biologicals Sa Epstein-barr virus antigen constructs
AU2019251356B2 (en) 2018-04-09 2025-06-12 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
EP3807298A1 (en) 2018-06-12 2021-04-21 GlaxoSmithKline Biologicals S.A. Adenovirus polynucleotides and polypeptides
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
EP3587581A1 (en) 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
CN112437684A (zh) 2018-07-20 2021-03-02 扬森疫苗与预防公司 以提高的生产率表达寨卡抗原的重组腺病毒载体
GB201812647D0 (en) * 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
WO2020079234A1 (en) 2018-10-19 2020-04-23 Nouscom Ag Teleost invariant chain cancer vaccine
MX2021005607A (es) 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
CA3114265A1 (en) 2018-11-15 2020-05-22 Nouscom Ag Selection of cancer mutations for generation of a personalized cancer vaccine
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP3934687A1 (en) 2019-03-05 2022-01-12 GlaxoSmithKline Biologicals S.A. Hepatitis b immunisation regimen and compositions
US12329793B2 (en) * 2019-03-20 2025-06-17 National University Corporation Hokkaido University Modified adenovirus and medicine comprising same
AU2020282369A1 (en) * 2019-05-30 2022-01-20 Seattle Project Corp. Modified adenoviruses
WO2021092095A1 (en) * 2019-11-04 2021-05-14 Gritstone Oncology, Inc. Neoantigen vaccine therapy
PH12022551208A1 (en) 2019-11-18 2023-04-24 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
CN113088530A (zh) * 2020-01-08 2021-07-09 怡道生物科技(苏州)有限公司 一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法
BR112022014808A2 (pt) 2020-01-31 2022-09-20 Beth Israel Deaconess Medical Ct Inc Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
JP2023521194A (ja) 2020-04-13 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用
KR20230009445A (ko) 2020-05-11 2023-01-17 얀센 파마슈티칼즈, 인코포레이티드 안정화된 코로나바이러스 스파이크 단백질 융합 단백질
IL299515A (en) 2020-06-29 2023-02-01 Janssen Vaccines & Prevention Bv Vaccine combination against respiratory syncytial virus infection
WO2022007774A1 (zh) * 2020-07-06 2022-01-13 嘉兴安宇生物科技有限公司 一种新型黑猩猩腺病毒载体及其构建方法和应用
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
EP4176087A1 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
WO2022008438A1 (en) 2020-07-06 2022-01-13 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
IL299571A (en) 2020-07-08 2023-02-01 Janssen Sciences Ireland Unlimited Co Rna replicon vaccines against hbv
CA3189238A1 (en) 2020-07-13 2022-01-20 Transgene Treatment of immune depression
WO2022032196A2 (en) * 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
EP4267605A2 (en) 2020-12-23 2023-11-01 Janssen Biotech, Inc. Neoantigen peptide mimics
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
WO2022175477A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
US20240197859A1 (en) 2021-04-01 2024-06-20 Janssen Vaccines & Prevention B.V. Stabilized Pre-Fusion PIV3 F Proteins
WO2022218997A1 (en) 2021-04-12 2022-10-20 Centre National De La Recherche Scientifique (Cnrs) Novel universal vaccine presenting system
AU2022299252A1 (en) 2021-06-21 2023-11-23 Nouscom Ag Vaccine composition comprising encoded adjuvant
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023026182A1 (en) 2021-08-24 2023-03-02 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
EP4448802A1 (en) 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
EP4598939A1 (en) 2022-10-06 2025-08-13 MSD International Business GmbH Stabilized pre-fusion piv3 f proteins
WO2025158316A1 (en) 2024-01-26 2025-07-31 Janssen Biotech, Inc. Ovarian neoantigens and use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0787200B1 (en) 1994-10-28 2005-04-20 The Trustees Of The University Of Pennsylvania Improved adenovirus and methods of use thereof
DK0863984T3 (da) * 1995-11-30 2006-08-28 Univ Texas Fremgangsmåder og præparater til behandling af cancer
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
JP4399255B2 (ja) * 2001-06-22 2010-01-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 細菌の形質転換体を迅速に選別する方法および新規なサルアデノウイルス蛋白質
DK1436397T3 (da) 2001-10-11 2010-08-09 Merck Sharp & Dohme Hepatitis C virus vaccine
HU230364B1 (hu) * 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
US20030224372A1 (en) 2002-05-31 2003-12-04 Denise Syndercombe-Court Method for determining ethnic origin by means of STR profile
RU2267496C2 (ru) 2004-01-15 2006-01-10 Сергей Иванович Черныш Противоопухолевые и антивирусные пептиды
DE602005017743D1 (de) * 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
WO2006086284A2 (en) 2005-02-11 2006-08-17 Merck & Co., Inc. Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby
JP5475279B2 (ja) * 2005-06-17 2014-04-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Ｃ型肝炎ウイルス核酸ワクチン
CA2706258C (en) * 2007-11-28 2017-06-06 The Trustees Of The University Of Pennsylvania Simian subfamily e adenoviruses sadv-39, -25.2, -26, -30, -37, and -38 and uses thereof
KR101614369B1 (ko) * 2007-11-28 2016-04-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 유인원 아과 ｃ 아데노바이러스 ｓａｄｖ-40, -31, 및 -34 및 그것의 사용
JP5661476B2 (ja) * 2008-03-04 2015-01-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
AU2009254168A1 (en) * 2008-06-03 2009-12-10 Okairos Ag A vaccine for the prevention and therapy of HCV infections

Also Published As

Publication number Publication date
RU2011136282A (ru) 2013-03-10
KR20110116144A (ko) 2011-10-25
IL241494A0 (en) 2015-11-30
IL214097B (en) 2018-08-30
US20200102352A1 (en) 2020-04-02
EP3385387A1 (en) 2018-10-10
US11214599B2 (en) 2022-01-04
AU2015238866B2 (en) 2017-05-25
US9718863B2 (en) 2017-08-01
IL214097A0 (en) 2011-08-31
BRPI1008018A2 (pt) 2016-03-15
MX2011007980A (es) 2011-08-17
AU2010209938A1 (en) 2011-08-25
US10544192B2 (en) 2020-01-28
CN102300872A (zh) 2011-12-28
SG172935A1 (en) 2011-08-29
NZ594355A (en) 2012-11-30
US20180057540A1 (en) 2018-03-01
CA2749325C (en) 2021-03-30
EP3385387B1 (en) 2021-08-25
KR101761425B1 (ko) 2017-07-26
WO2010086189A3 (en) 2010-09-23
AU2015238866A1 (en) 2015-10-29
KR20160110525A (ko) 2016-09-21
CA2749325A1 (en) 2010-08-05
JP2012516679A (ja) 2012-07-26
SG2014007959A (en) 2014-03-28
AU2017204292A1 (en) 2017-07-13
WO2010086189A2 (en) 2010-08-05
JP6262779B2 (ja) 2018-01-17
ES2898235T3 (es) 2022-03-04
CA3108979A1 (en) 2010-08-05
RU2604815C2 (ru) 2016-12-10
KR101763093B1 (ko) 2017-07-28
EP2391638A2 (en) 2011-12-07
AU2017204292B2 (en) 2019-02-07
EP2391638B1 (en) 2018-06-27
JP5882741B2 (ja) 2016-03-09
JP2016152801A (ja) 2016-08-25
US20120027788A1 (en) 2012-02-02
SI2391638T1 (sl) 2018-10-30

Similar Documents

Publication Publication Date Title
IL241494A0 (en) Nucleic acid and amino acid sequences of simian adenovirus, vectors containing them and their uses
IL271835B1 (en) Nonhuman great ape adenovirus nucleic acids and amino acid sequences and vectors containing them and their uses
ZA201104224B (en) Oncolytic adenoviral vectors and methods and uses related thereto
ZA201003461B (en) Poxviral oncolytic vectors
IL219042A (en) Epha4-derived peptide compounds
GB0712670D0 (en) Isolated peptides and uses thereof
ZA201004286B (en) Poxviral oncolytic vectors
IL210589A0 (en) The tuberculosis rv2386c protein, compositions and uses thereof
EP2170380A4 (en) CAPSID PROTEINS AND USES
IL213026A0 (en) TNA-a INHIBITING PEPTIDES, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF
PT2391638T (pt) Sequências de aminoácidos e ácidos nucleicos de adenovírus símio, vetores contendo as mesmas, e as suas utilizações
ZA201006443B (en) Novel immunoregularory peptides,compositions and uses thereof
IL207174A0 (en) Peptides, compositions, and uses thereof
HK1160155A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
GB0705969D0 (en) Insulated hooped hammock
AU313729S (en) Hair clip
GB0715352D0 (en) Clip wallet
IL182130A0 (en) Special hair clip for yarmulke
GB0816561D0 (en) Peptides and uses thereof
GB0709375D0 (en) Vector
GB0713954D0 (en) Multipad encryption